Trial Profile
A Phase 1/2 Study of Array 520 in Patients with Relapsed or Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Filanesib (Primary) ; Dexamethasone; Filgrastim
- Indications Multiple myeloma; Plasma cell leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Array BioPharma; Pfizer
- 17 Aug 2017 Results (Data cut off March 16, 2016) published in the Cancer
- 21 Apr 2016 Status changed from active, no longer recruiting to completed.
- 13 Feb 2014 Planned End Date changed from 1 Oct 2013 to 1 Jan 2014, as per ClinicalTrials.gov record.